Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

Abstract

Updated follow-up of the multicenter clinical study - Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: impact of subsequent therapy in the phase III VISTA trial

Keywords

• INTERNATIONAL STAGING SYSTEM
• STEM-CELL TRANSPLANTATION
• NEWLY-DIAGNOSED MYELOMA
• ELDERLY-PATIENTS
• PERIPHERAL NEUROPATHY
• IMPROVED SURVIVAL
• PROGRESSION-FREE
• YOUNGER PATIENTS
• THALIDOMIDE
• EFFICACY